MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3928/01913913-20251204-07

Медицинская библиотека · Journal of pediatric ophthalmology and strabismus · 2026

Characterizing the Treatment Courses of Ranibizumab and Panretinal Photocoagulation for Retinopathy of Prematurity.

Vought Victoria, Vought Rita, Crane Alexander B, Guo Suqin, Bhagat Neelakshi, Zarbin Marco A, Wagner Rudolph S

СтатьяПеревод в очереди

Аннотация

PURPOSE: This study characterizes the treatment course and outcomes of infants with retinopathy of prematurity (ROP) treated with ranibizumab, panretinal photo-coagulation (PRP), or combined therapy.

METHODS

This retrospective chart review analyzed electronic health record data of infants treated for ROP between 2016 and 2024 at a single academic center.

RESULTS

Thirty-seven infants (72 eyes) were analyzed (59.05% male, average 24.7 ± 1.4 weeks). At first treatment, most eyes were zone II, stage 3+ (59.7%). All eyes had plus disease except six treated for persistent avascular retina. PRP was administered as initial therapy for 30 (41.7%) eyes and ranibizumab for 42 (58.3%). Thirty-five eyes (48.6%) underwent only one treatment of either PRP (26 eyes; 36.1%) or ranibizumab (9 eyes; 12.5%). A second treatment consisting of ranibizumab was administered in 4 (13.3%) of 30 eyes treated with PRP and 21 (50%) of 42 eyes injected with ranibizumab. Eight eyes (11.1%) had three treatments: two ranibizumab injections followed by PRP. Four eyes (5.6%) had four treatments: three ranibizumab injections followed by PRP. ROP reactivation occurred in 14 (19.4%) eyes that all received ranibizumab injection initially (mean 50.6 ± 16.7 days after most recent injection). Final outcomes included PRP for persistent avascular retina in 22 (30.6%) eyes, unknown final outcomes due to lost follow-up for 16 (22.2%), documented resolution in 33 (45.8%), and scleral buckling for a peripheral retinal detachment (stage 4a) for one (1.4%).

CONCLUSIONS

Ranibizumab was initiated at a younger age with higher retreatment and reactivation events compared to PRP, underscoring variability in real-world ROP treatment patterns and outcomes.

Для цитирования: Vought Victoria, Vought Rita, Crane Alexander B, Guo Suqin, Bhagat Neelakshi, Zarbin Marco A, Wagner Rudolph S. Characterizing the Treatment Courses of Ranibizumab and Panretinal Photocoagulation for Retinopathy of Prematurity.. Journal of pediatric ophthalmology and strabismus. 2026. DOI: 10.3928/01913913-20251204-07.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.